



EBV-targeted cytotoxic T cells (CTLs) are a clinically advanced off-the-shelf, allogeneic T-cell immunotherapy that are highly amenable to expanding tumor antigen targeting through CAR transduction.

With high efficiency, we engineered EBV-CTLs to express second